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Abstract Professional physician organisations should be the
coordinators of all stakeholders involved in the field of
urogynaecology. That means that, together with representa-
tives of the patients (Bpatient organisations^) they develop a
priority agenda. This agenda involves the topics that need the
highest level of attention, either because knowledge in this
area is insufficient, or because existing knowledge is not op-
timally implemented. The next step is to discuss this list with
representatives of industry, patient representatives, insurance
companies and organisations with an intention to donate mo
ney to women’s health. Together, we can design a roadmap for
the coming years that involves the top priority topics that need
to be dealt with within the available budget. The organisations
facilitate the interaction between the different stakeholders,
communicate the timetable of these actions not only to their
members, but also to society at large.
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Introduction
Just a few weeks ago, Endo International decided to stop
selling the portfolio of Astora women’s health products and
close down the business (personal communication). Astora,
formerly known as the AMS women’s health division, was
the new corporate name for the business following the sale
of the AMS men’s health division and the AMS brand name
to Boston Scientific in mid-2015. Physicians, patients, pro-
fessional organisations, competitors and lawyers were all
surprised by the sudden decision undertaken by Endo.
How did it all start?
In the 1990s, physicians started to use mesh in vaginal surgery
to improve outcomes. Interest from industry followed and in
the early 2000s, the first commercial vaginal mesh kits were
introduced onto the market. The initial (underpowered)
studies with a short follow-up still showed superior anatomi-
cal outcomes [1]. The results were sufficient to generate much
attention among gynaecologists and urologists, who were not
only motivated to improve outcomes in their patients, but
were also interested in adopting new surgical procedures in
their existing, mostly narrow, surgical portfolio.
Professional organisations gained significant financial
benefits from the introduction of vaginal mesh surgery.
Sponsorship fees and financial support from industry for con-
gresses increased rapidly. Congress registration numbers in
turn increased rapidly because of industry sponsoring doctors’
attendance at international meetings. In addition, professional
organisation sessions and meetings sometimes lacked their
traditional scientific rigor and allowed podium presentations
of poorly designed studies including somewith very preliminary
results.
What happened after that?
Like all innovations, drawbacks become clear at the moment
at which implementation in a wider sphere occurred.
Physicians with less experience in pelvic floor surgery started
to perform vaginal mesh surgery on less appropriate patients
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(i.e., patients at a higher risk of complications or poor out-
comes).We know that these less experienced physicians never
blame themselves when a procedure has poor outcomes, but
instead blame the surgical technique. In my opinion, it is easy
to consider the physicians to be responsible for the overly
rapid introduction of new surgical procedures. We know that
there has been almost no improvement in surgical outcomes of
native tissue repair procedures over many decades. Given the
high number of procedures performed for recurrence, it is not
surprising that pelvic floor surgeons quickly placed vaginal
mesh surgery somewhere in their treatment protocol. For pro-
fessional organisations, these rapid and large-scale changes
are impossible to control. Some were very responsive in
designing public statements in reaction to the FDA notifica-
tions and public opinion.
What the professional organisations could have done dif-
ferently is to explain that vaginal mesh surgery may have had
an overly aggressive start, but that there was a second chance
to make a better start. Unfortunately, their response was the
opposite. Again, they did not follow science, and podiums
were provided to those who were most critical of mesh, were
never involved in studies evaluating mesh, and admitted that
they took more mesh out than they ever had placed. The same
happened with scientific journals, in which it was easier to
publish papers that were critical of mesh than papers
supporting the use of mesh.
In my opinion, the use of mesh in vaginal prolapse surgery
is better supported by data than sacrospinous fixation, laparo-
scopic sacrocolpopexy or the McCall procedure, all far more
frequently performed techniques [2].
Many organisations missed an opportunity to proactively
manage the public mesh debate. Instead of calling physicians
and industry together to discuss how the available resources
could be optimally used, they remained silent. Ultimately,
industry was forced to reduce its sponsorship budgets, includ-
ing the support of physicians attending annual scientific
meetings.
The role of the patient
The patient is the one who has the most to lose in this debate.
The patient is also the one for whom it is most difficult to
determine what to believe and what not to believe. Indeed,
there are many women who have suffered from an overly
rapid introduction of a new surgical technique that was not
yet ready to implement in daily clinical practice. In the (social)
media, these women are over-represented. Although physi-
cians say these Bmedia^ patients are not typical and not rep-
resentative, our patients identify with them.
Apart from the patients with mesh complications, those
who have no symptoms suffer as well. They live daily with
the fear that one of those terrible complications may still
happen to them. They question whether they should find a
doctor who can remove their mesh. In addition, women suf-
fering from pelvic organ prolapse, especially those with a
recurrence, choose to continue to suffer from their symptoms
rather than undergoing such a dangerous surgical procedure.
The role of industry
One misconception is that industry has used doctors and
patients to sell their products. If industry is not interested in
selling its products, it is an unreliable partner. If we believe in
the products, we should offer them to as many women as
possible to their benefit, and if we have doubts about the
product, we should research them better before offering them
to our patients and their potential complications. Industry can-
not do more than meet the requirements that physicians and
professional organisation have defined as minimal standards
to gain access to the market with a surgical technique. If we do
not work harder to optimise those requirements, we only have
ourselves to blame.
Pelvic floor implants are relatively inexpensive [3].
Worldwide, it is estimated that 90,000 perigees were sold at
an average of US$ 900, which implies that US$ 81 million
were earned in the lifecycle of this product. In comparison: an
antimuscarinic drug generates more than US$ 20 billion over
the lifetime of the patent.
It is clear that the resources available for developing and
performing clinical studies, etc., for a pelvic floor implant
are related to the profit that can be made. Implants for dif-
ferent indications such as hip implants, heart valves,
neurostimulators result in significantly greater profits. The
reasons for this may be speculated upon, but one reason
might be that the social awareness and impact of a condition
determines the willingness of society to address a medical
condition and to pay for better solutions. In addition, the
more profit industry can generate from a health problem,
the faster the health problem is solved, and the better the
available treatment options for patients.
We now live in an era where we should be happy that
companies are still interested in working in the field of pelvic
floor medicine. Again, we should not blame industry, but our-
selves, as we have not supported those who have left the
playing field or at least asked them how we can offer support.
With that, not only their current commercial products, but also
their budgets, research and development projects, and their
innovative insights have disappeared.
The fact that industry is losing interest in pelvic floor
medicine, is a threat to our future and our patients. We should
seek to reverse this and make pelvic floor medicine attractive
again to industry. The more interest we can generate within
industry with regard to the physical problems of our patients,
the faster we can bring better options to our patients.
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The role of urogynaecology organisations
Professional physician organisations should be the coordina-
tors of all the stakeholders involved in the field of
urogynaecology. This means that together with representa-
tives of the patients (Bpatient organisations^) they develop a
priority agenda. This agenda involves the topics that need the
greatest attention, either because knowledge is insufficient, or
because existing knowledge is not optimally implemented.
The next step is to discuss this list with representatives of
industry, patient representatives, insurance companies, and or-
ganisations with an intention to donate money to women’s
health. Together, we can design a roadmap for the coming
years that involves the top priority topics that need to be
answered within the available budget. The professional orga-
nisations facilitate the interaction between the different stake-
holders and communicate the timetable of these actions not
only to their members, but also to society at large [4].
By sharing our roadmap and efforts to make progress in our
field with the general public, society becomes a stakeholder as
well. If unexpected adverse outcomes of vaginal mesh surgery
had happened within an infrastructure as described here, soci-
ety would have known that a promising surgical technique is
under evaluation, and would have understood that as a result
of adverse events, wide implementation of mesh surgery is not
yet feasible. The reputation of urogynaecology would have
benefitted from such an infrastructure. Today, we appear to
be disorganised owing to a lack of coordination and
leadership.
It is not too late; we need a mindshift. The relationship
with industry cannot be opportunistic and unidirectional.
We do not have the skills, time or energy to create new
technology in combination with our work as physicians.
Some of us may have good ideas, some even a brilliant
ideas, but we need to collaborate from the beginning, to
make sure that there is mutual benefit, otherwise there is
no incentive to be involved in the field of medicine. We
should not be ashamed to explain this to our patients;
furthermore, we should introduce them to industry, so that
industry can work on solutions that meet the demands and
needs of our patients. We need to work on requirements
for the safe introduction of products, and collaborate on
realising these requirements. Professional organisations
are the connector, the facilitator and the bridge to society,
whose attention is urgently needed, to help us solve the
problems of patients with pelvic floor problems world-
wide, who deserve the best solutions.
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